EML4-ALK fusion gene and non-small cell lung cancer
10.3724/SP.J.1008.2014.00898
- Author:
Jing ZHAO
1
Author Information
1. Department of Pathology, Changhai Hospital, Second Military Medical University
- Publication Type:Journal Article
- Keywords:
EML4-ALK;
Fusion gene;
Non-small cell lung cancer
- From:
Academic Journal of Second Military Medical University
2014;35(8):898-900
- CountryChina
- Language:Chinese
-
Abstract:
The fusion gene of echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase(ALK) has recently been identified as a new molecular target for non-small cell lung cancer (NSCLC). EML4-ALK fusion gene is about 3%-11% in patients with NSCLC, and it has a higher morbidity in NSCLC patients who are young, without or with light smoking history and with adenocarcinomas. EML4-ALK positive NSCLC patients may be treated with ALK inhibitor (crizotinib). This review focuses on the biology, detection method, clinical characteristics and the therapeutic application of EML4-ALK in NSCLC.
